Recent advances in molecular pathology have had a significant impact on the diagnosis, classification, and treatment of soft tissue tumors. The practical application of these discoveries promises to assist greatly in the evaluation and treatment of soft tissue neoplasms in the head and neck region-an area characterized by exceedingly complex anatomy that often restricts the ample sampling of lesions and complete surgical resection. This reviews details some ways in which molecular techniques have strengthened conventional diagnostic and management approaches to low-grade fibromyxoid sarcoma, angiomatoid (malignant) fibrous histiocytoma, and dermatofibrosarcoma protuberans, all of which may involve the head and neck region.
Introduction
The past 10-15 years have seen a number of important advances in our understanding of the classification, diagnosis and etiopathogenesis of soft tissue tumors. Although important advances continue to be made in traditional clinicopathological (morphological) study and immunohistochemistry, the greatest breakthroughs have been in molecular pathology and genetics. This article will thus focus on 3 soft tissue tumors, low-grade fibromyxoid sarcoma, angiomatoid (malignant) fibrous histiocytoma, and dermatofibrosarcoma protuberans, tumors which highlight some of the ways in which advances in molecular genetics have improved our ability to diagnose and treat these rare mesenchymal lesions, while at the same time raising intriguing new questions. The differential diagnosis of these tumors is covered in widely available textbooks and will not be discussed.
Low-grade fibromyxoid sarcoma

Clinical features
Low-grade fibromyxoid sarcoma (LGFMS), initially described by Evans in 1987, is a rare soft tissue tumor characterized by a deceptively banal appearance and potential for late metastases.
LGFMS most often occur in young adults, but affect children in ~20% of cases. Most tumors involve the deep soft tissues of the extremities, but LGFMS may occur in any location, including the head and neck, and may on rare occasions involve superficial soft tissues, particularly in children. The overall metastatic risk for LGFMS is approximately 15%, although metastases may occur very late (>20 years after diagnosis), necessitating essentially indefinite clinical follow-up for patients with this disease. In general, LGFMS should be treated as one would other low-grade sarcomas, with wide excision and possible adjuvant radiotherapy. A role for systemic therapy has not been established for LGFMS.
Pathological features
The morphologic diagnosis of LGFMS may be challenging, owing to its typically low cellularity, abundant collagen, and relatively bland cytology. Most cases grow in a circumscribed but subtly infiltrative fashion ( Figure 1A) , and consist of an admixture of hypocellular, heavily collagenized zones containing widely spaced, monomorphic spindled cells, and more cellular myxoid nodules, containing a greater number of neoplastic cells arrayed about a characteristic curvilinear vasculature ( Figure 1B ). Clues to the diagnosis of LGFMS include the "abrupt" transition from collagenized zones into myxoid nodules, and the presence of small arteriole-sized vessels with concentric hyalinization, often producing distorted, angulated lumens. Although the cells of LGFMS are almost always monomorphic and bland-appearing, careful inspection invariably shows hyperchromatism and nuclear irregularity. Mitotic activity is typically very low and necrosis is absent. Morphologic features seen in a minority of cases include areas of increased cellularity and nuclear atypia approaching those seen in intermediate to highgrade fibrosarcoma, hyalinization, epithelioid morphology and a cord-like growth pattern (sclerosing epithelioid fibrosarcoma-like), and the presence of giant collagen rosettes (so-called "hyalinizing spindle cell tumor with giant rosettes) ( Figure 1C ).
Immunohistochemical features
In general, LGFMS show a purely fibroblastic immunophenotype, with expression only of vimentin. Expression of epithelial membrane antigen (EMA) has been documented in up to 40% of LGFMS in one study, a finding that has not been confirmed by other studies.
Potential expression of EMA has obvious implications for the distinction of LGFMS from one of its principal morphologic mimics, perineurioma. A very recent study has also reported expression of the perineurial-associated tight junction protein claudin-1 in genetically proven LGFMS, a finding at variance with prior studies and with the known absence of tight junctions in fibroblastic cells. We have not seen expression of EMA and claudin-1 in LGFMS in our own practices, but recommend caution in the use of these immunohistochemical reagents until further studies have addressed this important issue.
Genetic features
The diagnosis of LGFMS may be very challenging, and there has thus been considerable interest in identifying diagnostically useful genetic markers of this tumor. In 2000 Bejarano and colleagues reported the reciprocal translocation t(7;16) in a rosettecontaining LGFMS, a finding quickly followed by a report of a metastatic LGFMS to the lung bearing a ring chromosome derived from chromosomes 7 and 16. These early reports were confirmed by Reid et al, who identified this t(7;16)(q34;p11) in 4 LGFMS ( 
Angiomatoid (malignant) fibrous histiocytoma
Clinical features
Angiomatoid (malignant) fibrous histiocytoma (AMFH), a very rare mesenchymal tumor of uncertain differentiation, is considered a tumor of borderline/intermediate malignancy, owing to its significant potential for local recurrence, but <2% risk of metastasis. AMFH most often presents in children and young adults, as a small, superficial mass, occasionally mistaken clinically for a long-standing hematoma or vascular tumor. AMFH may present with systemic symptoms (fevers, weight loss, anemia, polyclonal gammopathy and a Castleman disease-like lymphadenopathy), which are due to cytokine production by the neoplastic cells and resolve following resection. AMFH require prompt wide excision to reduce the risk of local recurrence. Metastases to lymph nodes and distant locations (lung, bone, soft tissue) are seen in <2% of patients; the prognosis for these patients may still be excellent if these metastases can be completely resected. AMFH of the head/neck may have a worse prognosis, owing to difficulties in achieving complete resection in these anatomical locations.
Pathological features
Grossly, AMFH tend to be relatively well-circumscribed, pigmented and variably cystic. 
Immunohistochemical features
AMFH shows a unique immunophenotype, with co-expression of desmin, epithelial membrane antigen and CD68 in 50-60% of cases ( Figure 2C ). CD99 may also be positive. Although expression of muscle actins may be seen, AMFH do not express specific markers of skeletal muscle differentiation, such as myogenin, MyoD1, myoglobin or fast myosin. This is critical in their distinction from rhabdomyosarcoma, a frequent concern in a desmin-positive pediatric neoplasm. Markers of dendritic cell differentiation, such as CD21, CD35, clusterin, and S100 protein are absent. Approximately 8% of DFSP cases are fusion-negative; it remains to be seen if these rare cases contain cryptic rearrangements of COL1A1 and PDGFB or altogether different genetic abnormalities.
Genetic features
Conclusions
LGFMS, AMFH and DFSP, soft tissue tumors which may involve the head/neck region, exemplify some of the exciting ways in which advances in molecular genetics have impacted our ability to diagnose, classify, and treat patients with soft tissue tumors. From a diagnostic perspective, FISH for FUS provides a "gold standard" for the diagnosis of
LGFMS, a tumor which may otherwise be quite difficult to distinguish from various morphologic mimics, including perineurial tumors, myxomas, and desmoid-type 
